Hyperpolarized 129Xe MRI Lung Health Cohort

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Kansas Medical Center
Study ID
NCT05766384
Status
Recruiting
Apply to this trial

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
25 Years - 35 Years
Healthy Volunteers
Not accepted

Interventions

  • Hyperpolarized Xe129 — DRUG
    Inhaled hyperpolarized 129Xe used as a signal agent for MRI of the lungs.

Study Details

A subset of young adults participating in the American Lung Association (ALA) Lung Health Cohort (LHC) will be imaged using Hyperpolarized 129Xe MRI to assess lung structure and function. Images will be used to improve the understanding of lung health and early lung abnormalities that may lead to chronic lung disease.

Key Dates

Start date
Nov 30, 2023
Status verified
Apr 2026
Primary completion
Mar 31, 2027
Completion
Mar 31, 2027

Study Design

Enrollment
260 participants (estimated)

Primary Outcome Measure

Xe-MRI Apparent Diffusion Coefficient [ Time Frame: At baseline imaging timepoint ]

Central Contacts

Locations (6)

FacilityCityStateZIPSite coordinators
University of Illinois-ChicagoChicagoIllinois60607
Debby Cogley, MPH
[email protected]
312-996-9083
University of IowaIowa CityIowa52242
Eric Garcia
[email protected]
319-384-8610
University of Kansas Medical CenterKansas CityKansas66160
Cristal Monge
[email protected]
913-945-9399
Duke UniversityDurhamNorth Carolina27708
Kaitlin Foy
Kaitlin Mae Foy <[email protected]>
919-479-0861
Baylor College of MedicineHoustonTexas77030
Laura Bertrand
[email protected]
713-798-4951
MD Anderson Cancer CenterHoustonTexas77030
Jhankruti Desai, MPH
[email protected]
877-632-6789

Find similar trials in Chicago, IL

By research site
University of Illinois-Chicago· Chicago, ILUniversity of Iowa· Iowa City, IAUniversity of Kansas Medical Center· Kansas City, KSDuke University· Durham, NCBaylor College of Medicine· Houston, TXMD Anderson Cancer Center· Houston, TX

Related Studies